Author Affiliations: Critical Care Medicine Department, Clinical Center, and Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (Drs Barnett and Machado); and Division of Cardiology, University of California, San Francisco (Dr Hsue).
Modern health care has greatly increased longevity for patients with congenital hemolytic anemias (such as sickle cell disease and thalassemia) and human immunodeficiency virus (HIV) infection. It is estimated that 10% of patients with hemoglobinopathies and 0.5%
of patients with HIV infection develop moderate to severe pulmonary hypertension. Pulmonary hypertension is a relentlessly progressive disease leading to right heart failure and death. Worldwide, there are an estimated 30 million patients with sickle cell disease or thalassemia and 40 million patients with HIV disease. Considering the prevalence of pulmonary vascular disease in these populations, sickle cell disease and HIV disease may be the most common causes of pulmonary hypertension worldwide. In this review, the available data on epidemiology, hemodynamics,
mechanisms, and therapeutic strategies for these diseases are summarized.
Because therapy is likely to reduce morbidity and prolong survival,
efforts to screen, diagnose, and treat these patients represent a global health opportunity.
Barnett CF, Hsue PY, Machado RF. Pulmonary HypertensionAn Increasingly Recognized Complication of Hereditary Hemolytic Anemias and HIV Infection. JAMA. 2008;299(3):324-331. doi:10.1001/jama.299.3.324